Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 5,983 shares at $0.80 ($5K) on 2019-02-04, disclosed to the SEC on 2019-02-06.
Open-market purchase of $5k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |